+987.9%
MRNA vs CVE
+73.4%
+914.6%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | CVE | Excess | Alpha |
|---|---|---|---|---|
| 1D | +13.1% | -7.6% | +20.8% | +11.8% |
| 7D | +20.6% | -12.1% | +32.7% | +18.6% |
| 30D | +27.1% | -9.8% | +36.9% | +25.7% |
| 3M | +353.4% | -0.7% | +354.1% | +346.9% |
| 6M | +446.3% | -4.3% | +450.6% | +451.9% |
| YTD | +776.2% | +70.6% | +705.6% | +560.4% |
| 1Y | +987.9% | +73.2% | +914.8% | +689.1% |
| All | +987.9% | +73.4% | +914.6% | +689.1% |
Cumulative growth
Daily Returns
Daily percentage return beside CVE.
Daily Out/Under-Performance
Portfolio return minus CVE return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × CVE return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded CVE wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling